Trials / Terminated
TerminatedNCT01605318
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Labetuzumab Govitecan (LG) | Administered as a slow intravenous (IV) infusion. |
Timeline
- Start date
- 2013-02-12
- Primary completion
- 2017-01-03
- Completion
- 2017-01-03
- First posted
- 2012-05-24
- Last updated
- 2024-01-24
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01605318. Inclusion in this directory is not an endorsement.